Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Circuit Clinical

Neither a doctor nor a teaching hospital

Research payments

$1,612,881

192 payments

Through program year 2025, Circuit Clinical is reported as receiving $1,612,881 in research payments, across 192 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $527,304 23
2024 Research $248,592 12
2023 Research $580,716 48
2022 Research $23,053 2
2021 Research $16,005 5
2020 Research $51,126 49
2019 Research $166,086 53

Breakdown

Who paid Research payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $748,487 38 payments
  2. GlaxoSmithKline, LLC. $580,156 19 payments
  3. Visby Medical, Inc. $58,610 4 payments
  4. Shire North American Group Inc $51,789 28 payments
  5. Incyte Corporation $30,523 8 payments
  6. Abbott Laboratories $26,686 2 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $24,657 45 payments
  8. AstraZeneca UK Limited $23,841 2 payments
  9. Genentech, Inc. $21,608 13 payments
  10. Ironwood Pharmaceuticals, Inc $17,533 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 1/2, First-Time-In Human (Ftih), Randomized, Observer-Blind, P $490,817 16 payments
  2. A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin FDC Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease and High Proteinuria $141,857 8 payments
  3. a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure $123,470 6 payments
  4. a twelfeweek randomized doubleblind phase four study evaluating the effect of airsupra compared to albuterol administered as needed on changes in airway inflammation symptoms and rescue therapy utilization in adults with mild asthma darwin $92,753 3 payments
  5. A Phase 3, Open-Label, Randomized, Controlled, Multi Country Study to $89,339 3 payments
  6. a phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non small cell lung cancer patients with non squamous histology who have mutations and or co mutations in skt11,keap1,or kras triton $78,593 1 payment
  7. Levante A Phase 2b Randomised Double Blind Placebo Controlled Dose Range Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630 $72,966 3 payments
  8. A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma $47,451 3 payments
  9. A Multinational Randomised Double Blind Placebo Controlled Trial to Evaluate the Effect of Ticagrelor 90 mg twice daily on the Incidence of Cardiovascular Death Myocardial Infarction or Stroke in Patients with Type 2 Diabetes $45,507 3 payments
  10. Clinical Evaluation of the Visby Medical Respiratory Health Test for the Detection and Differentiation of SARS-CoV-2, Influenza A and Influenza B Viral RNA $35,557 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record